Prostaglandin E1 in conjunction with high doses of vitamin B12 improves nerve conduction velocity of patients with diabetic peripheral neuropathy

Neural Regeneration Research

Volumn 3, Issue 5, 2008, Pages 529-532

  Li, Jilai ^a   Wan, Zhirong ^a  

^a Department of Neurology   (China)

Author keywords

Diabetes mellitus; Diabetic peripheral neuropathy; Prostaglandin E1; Vitamin B12

Indexed keywords

ANTIDIABETIC AGENT; CYANOCOBALAMIN; GLUCOSE; INSULIN; PROSTAGLANDIN E1; SODIUM CHLORIDE; THIAMINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC DIET; DIABETIC NEUROPATHY; DRUG EFFICACY; DRUG MEGADOSE; ELECTROMYOGRAM; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INJECTION SITE IRRITATION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDIAN NERVE; MOTOR NERVE CONDUCTION; NERVE CONDUCTION DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; PAIN; PERONEUS NERVE; RANDOMIZED CONTROLLED TRIAL; SENSORY NERVE CONDUCTION; SYMPTOMATOLOGY;

EID: 69749092245     PISSN: 16735374     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Itoh Y, Yasui T, Kakizawa H, et al. The therapeutic effect of lipo PGE1 on diabetic neuropathy-changes in endothelin and various angiopathic factors. Prostaglandins Other Lipid Mediat 2001;66(3):221-34
2. Carlson LA, Olsson AG. Intravenous prostaglandin E1 in severe peripheral vascular disease. Lancet 1976;2(7989):810
3. Taveggia G, Selletti L. Therapeutic effects of prostaglandin E1 in diabetic patients. Minerva Cardioangiol 2003;51(3):317-22
4. Akahori H, Takamura T, Hayakawa T, et al. Prostaglandin E1 in lipid microspheres ameliorates diabetic peripheral neuropathy: clinical usefulness of Semmes-Weinstein monofilaments for evaluating diabetic sensory abnormality. Diabetes Res Clin Pract 2004;64(3):153-9
5. Shindo H, Tawata M, Inoue M, et al. The effect of prostaglandin E1.alpha CD on vibratory threshold determined with the SMV-5 vibrometer in patients with diabetic neuropathy. Diabetes Res Clin Pract 1994;24(3):173-80
6. Zhong HJ, Han XY, Fang YC, et al. The treatment of diabetic neuropathy with PGE1. Zhonghua Neifenmi Daixie Zazhi 1995;11(2):115-6
7. Qian RL. New criteria of diagosis and typing of diabetes mellitus. Zhongguo Tangniaobing Zazhi 2000;18(1):5-6
8. Eguchi S, Kawano T, Yinhua, et al. Effects of prostaglandin E1 on vascular ATP-sensitive potassium channels. J Cardiovasc Pharmacol 2007;50(6):686-91
9. Gabbay KH. Aldose reductase inhibition in the treatment of diabetic neuropathy: where are we in 2004? Curr Diab Rep 2004;4(6):405-8
10. Tomlinson DR, Gardiner NJ. Glucose neurotoxicity. Nat Rev Neurosci 2008;9(1):36-45
11. Moretti R, Torte P, Antonello RM, et al. Vitamin B12 and folate depletion in cognition: a review. Neurol India 2004;52(3):310-8
12. Beijing Methycobal Clinical Trial Collaborative Group. Effect of mecobalamin on diabetic neuropathies. Zhonghua Neike Zazhi 1999;1:14
13. Sun YZ, Liu TT. Comparison of therapeutic effects of acupuncture and moxibustion on diabetic peripheral neuropathies. Zhongguo Zhen Jiu 2005;25(8):539-41
14. Federici T, Boulis N. Gene therapy for peripheral nervous system diseases. Curt Gene Ther 2007;7(4):239-48
15. Thiam A, Diagne M, Sene Diouf F. Diabetic neuropathies in Neurological Clinic of Dakar. Dakar Med 2005;50(3):108-12